Status:
UNKNOWN
Liquid Biopsy in Hepatocellular Carcinoma
Lead Sponsor:
Post Graduate Institute of Medical Education and Research, Chandigarh
Conditions:
Hepatic Carcinoma Malignant Primary Non-Resectable
Eligibility:
All Genders
18-70 years
Brief Summary
Circulating tumor DNA (ctDNA) carrying tumor-specific sequence alterations has been found in the cell-free fraction of blood. Hepatocellular carcinoma (HCC) specimens are difficult to obtain, and noni...
Detailed Description
Novelty: Mutation analysis may not only help identify cancer drivers, but they can also provide useful data to predict response to other treatment modalities such as immunotherapies, particularly imm...
Eligibility Criteria
Inclusion
- Hepatocellular carcinoma BCLC stages B and C of all aetiology, unresectable
- Age 18-70 years of either sex
Exclusion
- Contemplating Hepatic resection or OLT
- Refractory ascites
- Severe Coagulation disorders prior to the procedure (PTI \<70% and Platelet count \< 80,000/mm3)
- Hepato-Renal syndrome
- Chronic Kidney Disease
- Acute decompensation like Hepatic encephalopathy and variceal bleeding
- Any known malignancy other than HCC
- Life expectancy \< 6 months
Key Trial Info
Start Date :
January 16 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 1 2024
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT04111029
Start Date
January 16 2020
End Date
March 1 2024
Last Update
May 3 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Postgraduate Institute of Medical Education and Research
Chandigarh, Choose Any State/Province, India, 160012